脂質調節劑市場- 依類型（他汀類藥物[品牌、組合]、非他汀類藥物[纖維酸衍生物、膽汁酸]）、依適應症（高膽固醇血症、冠狀動脈疾病）、依給藥途徑、配銷通路與預測，2024 年- 2032

Lipid Regulators Market - By Type (Statins [Branded, Combination], Non-statins [Fibric-acid Derivatives, Bile-acid]), By Indication (Hypercholesterolemia, Coronary Artery Disease), By Route of Administration, Distribution Channel & Forecast, 2024 - 2032

出版日期: 2024年03月08日 | 出版商:

Global Market Insights Inc. | 英文 203 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於不健康飲食、久坐的生活方式和人口老化等因素，心臟病和中風等心血管疾病的盛行率不斷上升，預計2024年至2032年期間，脂質調節劑市場規模將以3.8%的複合年成長率成長。根據 CDC 的數據，美國每 40 秒就有一人心臟病發作，每年約有 805,000 人心臟病發作。脂質調節劑是幫助控制膽固醇水平並降低心血管事件風險的藥物。

醫療保健專業人員和患者對血脂管理重要性的認知不斷提高，導致診斷和治療率提高。此外，旨在促進心血管健康的有利政府舉措，例如公共衛生運動、篩檢計畫和調脂藥物的報銷政策，將在推動市場成長方面發揮重要作用。這些措施有助於提高意識，改善醫療保健服務的可近性，並減輕心血管疾病的經濟負擔，進一步鼓勵採用血脂調節劑。

整個市場根據類型、適應症、配銷通路、給藥途徑和區域進行分類。

從給藥途徑來看，注射型脂質調節劑產業預計到2032 年複合年成長率將達到3.1%。治療選擇血脂水平。此外，注射製劑通常提供更一致和可預測的吸收，從而改善治療結果和患者依從性。

從配銷通路來看，2024年-2032年，網路藥局血脂調節劑市場將錄得4.5%的成長率。網路藥局提供的便利性和可近性使患者更容易獲得調脂藥物，從而提高治療的依從性和依從性。患者可以輕鬆地在線訂購處方並將其送到家門口，同時無需頻繁前往傳統的實體藥局。此外，線上藥局提供有競爭力的價格和折扣，使血脂調節劑對患者來說更實惠和有吸引力。

由於心血管疾病和肥胖和久坐生活方式等相關危險因子的盛行率不斷增加，歐洲脂質調節劑產業在2024年至2032年間將以4.4%的複合年成長率快速擴張。嚴格的醫療保健法規和指南強調膽固醇管理的重要性，透過促進脂質疾病的早期診斷和治療，促進了對脂質調節劑的需求。藥品研發的不斷進步，加上新型調脂療法的推出，可能會進一步刺激區域產業擴張。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 10 章：公司簡介

AbbVie Inc
Amgen Inc.
AstraZeneca plc
Bristol-Myers Squibb
Dr. Reddy's Laboratories Ltd.
Merck & Co.
Novartis AG
Pfizer, Inc.
Sanofi
Teva Pharmaceuticals

簡介目錄

Product Code: 8442

Lipid regulators market size is anticipated to grow at 3.8% CAGR between 2024 and 2032, driven by the increasing prevalence of cardiovascular diseases, such as heart attacks and strokes, due to factors like unhealthy diets, sedentary lifestyles, and aging populations. As per CDC, every 40 seconds, an individual in the U.S. experiences a heart attack, totaling approximately 805,000 people annually. Lipid regulators are medications that help manage cholesterol levels and reduce the risk of cardiovascular events.

The rising awareness about the importance of lipid management among healthcare professionals and patients has led to increased diagnosis and treatment rates. Moreover, favorable government initiatives aimed at promoting cardiovascular health, such as public health campaigns, screening programs, and reimbursement policies for lipid-regulating medications will play a significant role in driving market growth. These initiatives help raise awareness, improve access to healthcare services, and reduce the economic burden of cardiovascular diseases, further encouraging the adoption of lipid regulators.

The overall market is classified based on type, indication, distribution channel, route of administration and region.

By route of administration, the lipid regulators industry from the injectable segment is anticipated to witness 3.1% CAGR through 2032. Injectable lipid regulators offer a convenient and effective treatment option for patients who may have difficulty adhering to oral therapies or who require rapid and precise control of lipid levels. Additionally, injectable formulations often provide more consistent and predictable absorption, leading to improved therapeutic outcomes and patient compliance.

In terms of distribution channel, the lipid regulators market from the online pharmacies segment will record 4.5% growth rate during 2024 -2032. The convenience and accessibility offered by online pharmacies makes it easier for patients to access lipid-regulating medications, thereby increasing treatment adherence and compliance. Patients can conveniently order their prescriptions online and have them delivered to their doorstep while eliminating the need for frequent visits to traditional brick-and-mortar pharmacies. Additionally, online pharmacies offer competitive pricing and discounts, making lipid regulators more affordable and attractive to patients.

Europe lipid regulators industry will witness rapid expansion at 4.4% CAGR between 2024 and 2032, attributed to the increasing prevalence of cardiovascular diseases and related risk factors, such as obesity and sedentary lifestyles. Stringent healthcare regulations and guidelines emphasizing the importance of cholesterol management are contributing to the need for lipid regulators by promoting early diagnosis and treatment of lipid disorders. Rising advancements in pharmaceutical R&D coupled with the introduction of novel lipid-regulating therapies may further stimulate the regional industry expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of cardiovascular diseases
  - 3.2.1.2 Advancements in drug development
  - 3.2.1.3 Growing geriatric population
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects associated with lipid regulators
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Statins
- 5.2.1 Branded statins
- 5.2.2 Statin combination
- 5.2.3 Generic statins
5.3 Non-statins
- 5.3.1 Fibric-acid derivatives
- 5.3.2 Bile-acid sequestrants
- 5.3.3 Ezetimibe
- 5.3.4 Nicotinic acid derivatives
- 5.3.5 PCSK9 inhibitors
- 5.3.6 Other non-statins

Chapter 6 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Hypercholesterolemia
6.3 Hypertriglyceridemia
6.4 Coronary artery disease
6.5 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa